Skip to main
ABBV

AbbVie (ABBV) Stock Forecast & Price Target

AbbVie (ABBV) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 22%
Buy 56%
Hold 22%
Sell 0%
Strong Sell 0%

Bulls say

AbbVie demonstrates a positive financial outlook, with management projecting Neuroscience segment global sales to reach approximately $10.7 billion by 2025, an increase from previous expectations of $10.5 billion. The company has reported impressive global sales growth for key products, including Ubrelvy, Qulipta, and Botox Therapeutic, with figures indicating increases of around 32%, 64%, and 16%, respectively, year-over-year in Q3 2025. Additionally, the upward adjustments in estimates for Skyrizi and key Neuroscience products reflect AbbVie's robust prospects in both the immunology and aesthetics markets, underscoring the company's strategic position for future growth.

Bears say

AbbVie faces significant challenges due to anticipated erosion of Humira's market share from competing biosimilars beginning in 2025, which could severely impact revenue projections. The company's key products, Rinvoq and Skyrizi, are struggling to penetrate the market effectively, particularly in inflammatory bowel disease, raising concerns about achieving long-term growth targets. Additionally, broader macroeconomic pressures, such as competition in the aesthetics market and pipeline setbacks in its research and development phases, contribute to a negative outlook for AbbVie's financial performance.

AbbVie (ABBV) has been analyzed by 18 analysts, with a consensus rating of Buy. 22% of analysts recommend a Strong Buy, 56% recommend Buy, 22% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AbbVie and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AbbVie (ABBV) Forecast

Analysts have given AbbVie (ABBV) a Buy based on their latest research and market trends.

According to 18 analysts, AbbVie (ABBV) has a Buy consensus rating as of Apr 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $251.89, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $251.89, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AbbVie (ABBV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.